9.84
-0.25(-2.48%)
Currency In USD
| Previous Close | 10.09 |
| Open | 9.95 |
| Day High | 10.25 |
| Day Low | 9.62 |
| 52-Week High | 10.73 |
| 52-Week Low | 2.24 |
| Volume | 469,810 |
| Average Volume | 1.24M |
| Market Cap | 459.52M |
| PE | -2.79 |
| EPS | -3.53 |
| Moving Average 50 Days | 7.56 |
| Moving Average 200 Days | 5.04 |
| Change | -0.25 |
If you invested $1000 in 4D Molecular Therapeutics, Inc. (FDMT) since IPO date, it would be worth $242.96 as of October 19, 2025 at a share price of $9.84. Whereas If you bought $1000 worth of 4D Molecular Therapeutics, Inc. (FDMT) shares 3 years ago, it would be worth $1,419.91 as of October 19, 2025 at a share price of $9.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
GlobeNewswire Inc.
Oct 14, 2025 12:00 PM GMT
EMERYVILLE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatmen
4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation
GlobeNewswire Inc.
Oct 13, 2025 12:00 PM GMT
Cystic Fibrosis Foundation to provide up to $11 million in additional funding to accelerate development of 4D-710 for cystic fibrosis, following program and clinical data review by its independent scientific advisors Funding supports second 4D-710 do
4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness
GlobeNewswire Inc.
Sep 02, 2025 12:00 PM GMT
Julie Clark, M.D., promoted to Chief Medical Officer Liansheng Zhu, Ph.D., joined as SVP, Biometrics and Data Quality4FRONT-1 Phase 3 trial enrollment continues to exceed expectations, with enrollment completion now expected in Q1 2026 Addition of di